Actavis, AstraZeneca Settle Crestor Generic Suit

Law360, New York (March 25, 2013, 1:38 PM EDT) -- Actavis Inc. and Egis Pharmaceuticals PLC have reached an agreement with AstraZeneca UK Ltd. and Shionogi & Co. Ltd. to end Delaware patent litigation over a planned generic version of blockbuster cholesterol-reducing drug Crestor, the companies announced Monday.

Under the terms of the deal, Actavis will be allowed to launch its generic rosuvastatin calcium and rosuvastatin zinc alternate treatments, which it co-developed with Hungarian drugmaker Egis, on May 2, 2016 — 67 days before the expiration of AstraZeneca’s exclusivity period for the pediatric use of Crestor....
To view the full article, register now.